文献速递乳腺癌放疗

保乳术后接受紫杉类化疗的pN1乳腺癌患者全乳加区域淋巴结照射与单纯全乳照射的患者报告结局:一项随机3期临床试验(KROG 17-01)

Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-09-24

KROG 1701试验为3期多中心非劣效研究,纳入保乳术后接受紫杉类辅助化疗的pN1乳腺癌患者840例,随机接受全乳加区域淋巴结照射或单纯全乳照射。患者报告结局显示所有领域随时间改善(P<.001),放疗期间全乳加区域淋巴结照射组疲劳和恶心更明显,治疗后3个月手臂症状评分更高(P=.030),但两组差异无临床显著性。

要点

  • 放疗期间全乳加区域淋巴结照射组报告疲劳和恶心更明显。
  • 治疗后3个月全乳加区域淋巴结照射组手臂症状评分更高(P=.030)。
  • 两组其他患者报告结局领域包括手臂/乳房症状无显著差异。

核心结论

  • 在pN1乳腺癌接受紫杉类化疗的患者中,全乳照射加区域淋巴结照射导致特定患者报告结局领域轻微、暂时的下降,但这些差异无临床显著性。
  • 全乳加区域淋巴结照射与单纯全乳照射的整体患者体验相当,支持两种治疗的安全性和患者耐受性。

研究设计与样本

  • KROG 1701试验(NCT03269981)为3期、多中心、非劣效研究。
  • 纳入保乳术后接受紫杉类辅助化疗的pN1乳腺癌患者,分配至全乳加区域淋巴结照射组或单纯全乳照射组。
  • 2017年4月至2021年12月共入组840例,777例按分配接受干预,750例完成基线患者报告结局问卷(全乳加区域淋巴结照射组387例,单纯全乳照射组363例)。
  • 使用欧洲癌症研究与治疗组织生活质量核心30问卷和乳腺癌特异性模块23,在基线、放疗期间、后续随访间隔3至6个月及每年至4年评估患者报告结局。

主要发现

  • 所有患者报告结局领域随时间改善(P<.001)。
  • 放疗期间,全乳加区域淋巴结照射组报告疲劳和恶心更明显。
  • 治疗后3个月,全乳加区域淋巴结照射组手臂症状评分更高(P=.030)。
  • 两组其他患者报告结局领域包括手臂/乳房症状无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of regional node irradiation (RNI) with whole-breast irradiation (WBI) in patients with pN1 breast cancer receiving taxane-based adjuvant chemotherapy is not well defined. The KROG 1701 trial, a phase 3, multicenter, noninferiority study, aimed to compare the disease-free survival between WBI+RNI and WBI alone in this patient cohort. Comprehensive patient-reported outcomes (PROs) collected at multiple timepoints are reported. METHODS AND MATERIALS: The trial (NCT03269981) enrolled patients with pN1 breast cancer after breast-conserving surgery and taxane-based adjuvant chemotherapy, allocating them to receive either WBI+RNI or WBI only. PROs were assessed using European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaires Core 30and breast cancer-specific module 23 modules at baseline, during radiation therapy, and at subsequent follow-up intervals of 3 to 6 months, and annually up to 4 years. RESULTS: From April 2017 to December 2021, 840 patients were enrolled; 777 received intervention as assigned, and 750 completed baseline PRO questionnaires (387 in WBI+RNI, 363 in WBI only). All PRO domains showed improvements over time (P < .001). During radiation therapy, the WBI+RNI group reported greater fatigue and nausea. Higher arm symptom scores were observed in the WBI+RNI group 3 months post-treatment (P = .030). No other significant PRO domain differences, including arm/breast symptoms, were observed between the 2 groups. CONCLUSIONS: In patients with pN1 breast cancer treated with taxane-based chemotherapy, adding RNI to WBI resulted in minor, temporary declines in specific PRO domains, but these differences were not clinically significant. This indicates that overall patient experience between WBI+RNI and WBI is comparable, supporting the safety and patient tolerability of both treatments.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kim N, Park W, Kim H, et al. Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01). Int J Radiat Oncol Biol Phys. 2024. PMID: 39326505. doi:10.1016/j.ijrobp.2024.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。